| scholarly article | Q13442814 |
| P2093 | author name string | Tawfik Khoury | |
| Ariel A Benson | |||
| Saleh Daher | |||
| Muhammad Massarwa | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Oncolytic virus therapy: A new era of cancer treatment at dawn | Q26739714 | ||
| Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation | Q27014758 | ||
| Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies | Q27026025 | ||
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma | Q28247867 | ||
| Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling | Q28296761 | ||
| Effect of liver regeneration on malignant hepatic tumors | Q28651675 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis | Q29619508 | ||
| Primary liver cancer: worldwide incidence and trends | Q29620133 | ||
| Uterine leiomyomas: MR imaging-based thermometry and thermal dosimetry during focused ultrasound thermal ablation | Q30499143 | ||
| High intensity focused ultrasound for the treatment of rat tumours | Q50253925 | ||
| Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. | Q51021204 | ||
| Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. | Q51168197 | ||
| Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. | Q51257827 | ||
| Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. | Q51472261 | ||
| Tissue ablation with irreversible electroporation. | Q51528114 | ||
| Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. | Q51642133 | ||
| ALPPS for patients with colorectal liver metastases: effective liver hypertrophy, but early tumor recurrence. | Q51767547 | ||
| Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. | Q53112763 | ||
| PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. | Q54427872 | ||
| Tobacco smoking and cancer: A meta-analysis | Q56779419 | ||
| EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma | Q57756593 | ||
| Solid liver tumors | Q67551154 | ||
| A new fixation device for the Leksell stereotaxic system. Technical note | Q68944773 | ||
| Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy | Q78069258 | ||
| Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study | Q78873230 | ||
| Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation | Q81668582 | ||
| Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion | Q83368054 | ||
| Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings | Q83435113 | ||
| Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction | Q84341103 | ||
| Transarterial therapies for hepatocellular carcinoma | Q84917632 | ||
| Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q85009916 | ||
| Pearls and pitfalls on ALPPS procedure: new complications in a new technique | Q87388642 | ||
| Biliary sequelae following radioembolization with Yttrium-90 microspheres | Q47746491 | ||
| Radiosurgery of liver tumors: value of robotic radiosurgical device to treat liver tumors. | Q48809198 | ||
| Long-term outcome of transrectal high- intensity focused ultrasound therapy for benign prostatic hyperplasia | Q50252027 | ||
| Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience | Q50253182 | ||
| Histological changes in rat liver tumours treated with high-intensity focused ultrasound | Q50253704 | ||
| Review article: percutaneous treatment of hepatocellular carcinoma | Q30942931 | ||
| Percutaneous ablation of hepatocellular carcinoma: state-of-the-art | Q31040877 | ||
| A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. | Q33368982 | ||
| Extracranial stereotactic radiotherapy: preliminary results with the CyberKnife | Q33431153 | ||
| Current management of hepatocellular carcinoma | Q33582165 | ||
| Cyberknife stereotactic body radiation therapy for nonresectable tumors of the liver: preliminary results | Q34002010 | ||
| Systemic chemotherapy of liver tumors | Q34110952 | ||
| In vivo results of a new focal tissue ablation technique: irreversible electroporation | Q34546129 | ||
| Updates in the management of hepatocellular carcinoma | Q34571160 | ||
| Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma | Q34593071 | ||
| The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective | Q34625481 | ||
| Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience | Q34630506 | ||
| Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. | Q34655472 | ||
| Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes | Q35004090 | ||
| Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. | Q35164855 | ||
| DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma. | Q35197356 | ||
| Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation | Q35435327 | ||
| Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges | Q35501246 | ||
| Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less | Q35598182 | ||
| Focus on hepatocellular carcinoma. | Q35721877 | ||
| Updated treatment approach to hepatocellular carcinoma. | Q36097844 | ||
| Advanced hepatocellular carcinoma: treatment with high-intensity focused ultrasound ablation combined with transcatheter arterial embolization | Q36109501 | ||
| Resection and liver transplantation for hepatocellular carcinoma. | Q36140302 | ||
| Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice | Q36199751 | ||
| Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells | Q36742588 | ||
| TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer | Q36777331 | ||
| Strategies for safer liver surgery and partial liver transplantation | Q36788914 | ||
| Targeted therapies for hepatocellular carcinoma. | Q36928888 | ||
| Sorafenib for the treatment of unresectable hepatocellular carcinoma | Q37368694 | ||
| Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients | Q37420216 | ||
| Systemic therapies in hepatocellular carcinoma | Q37527632 | ||
| Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. | Q37565869 | ||
| Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives | Q37581334 | ||
| Hepatocellular carcinoma: A global view. | Q37589349 | ||
| Approach to radiation therapy in hepatocellular carcinoma | Q37661759 | ||
| Systemic therapy for advanced hepatocellular carcinoma: past, present, and future | Q37734197 | ||
| Future perspectives in hepatocellular carcinoma | Q37765050 | ||
| Advanced hepatocellular carcinoma. Review of targeted molecular drugs. | Q37837305 | ||
| Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). | Q37983026 | ||
| Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. | Q38004651 | ||
| Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate | Q38049924 | ||
| Emerging targeted strategies in advanced hepatocellular carcinoma | Q38086183 | ||
| Detection of epigenetic aberrations in the development of hepatocellular carcinoma | Q38271103 | ||
| Understanding the tumor suppressor PTEN in chronic alcoholism and hepatocellular carcinoma | Q38271796 | ||
| ALPPS: challenging the concept of unresectability--a systematic review | Q38286456 | ||
| The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications | Q38400354 | ||
| Sorafenib: 10 years after the first pivotal trial. | Q38544841 | ||
| Influence of P53 on the radiotherapy response of hepatocellular carcinoma. | Q38822712 | ||
| Should ALPPS be Used for Liver Resection in Intermediate-Stage HCC? | Q38934201 | ||
| Prediction of Mortality After ALPPS Stage-1: An Analysis of 320 Patients From the International ALPPS Registry | Q38941193 | ||
| Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification | Q39121343 | ||
| Hepatocellular carcinoma and chemotherapy: the role of p53. | Q39222765 | ||
| Short and long term efficacy of high intensity focused ultrasound therapy for advanced hepatocellular carcinoma | Q39327348 | ||
| Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): tips and tricks | Q39512848 | ||
| MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. | Q39528390 | ||
| Human augmenter of liver regeneration is important for hepatoma cell viability and resistance to radiation-induced oxidative stress | Q39823488 | ||
| Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma | Q39888328 | ||
| Circulating Hypermethylated RASSF1A as a Molecular Biomarker for Diagnosis of Hepatocellular Carcinoma | Q40149759 | ||
| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | Q40231174 | ||
| Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection | Q40757028 | ||
| Rapid improvement in liver volume induced by portal vein ligation and staged hepatectomy: the ALPPS procedure | Q41889876 | ||
| Can liver transplantation provide the statistical cure? | Q42259254 | ||
| Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? | Q42940992 | ||
| A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. | Q42989841 | ||
| Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. | Q43419259 | ||
| Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b | Q43449610 | ||
| Determinants of postembolization syndrome after hepatic chemoembolization | Q43565401 | ||
| Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients | Q44377962 | ||
| Using ALPPS to induce rapid liver hypertrophy in a patient with hepatic fibrosis and portal vein thrombosis | Q44609517 | ||
| Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. | Q45358316 | ||
| Cancer cells ablation with irreversible electroporation | Q45888645 | ||
| Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. | Q45913015 | ||
| Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival | Q46743120 | ||
| Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma | Q47409182 | ||
| Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model | Q47697970 | ||
| P433 | issue | 1 | |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 69-78 | |
| P577 | publication date | 2017-12-17 | |
| P1433 | published in | Journal of clinical and translational hepatology | Q27726496 |
| P1476 | title | Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. | |
| P478 | volume | 6 |
| Q92579754 | A network pharmacology-based study on the anti-hepatoma effect of Radix Salviae Miltiorrhizae |
| Q92326689 | Bioactivities of Geranium wallichianum Leaf Extracts Conjugated with Zinc Oxide Nanoparticles |
| Q92715403 | CCL20 is overexpressed in hepatocellular carcinoma with bile duct tumor thrombus and correlates negatively with surgical outcome |
| Q98159071 | Caprin-1 promotes HepG2 cell proliferation, invasion and migration and is associated with poor prognosis in patients with liver cancer |
| Q92016494 | Comparison of open liver resection and RFA for the treatment of solitary 3-5-cmhepatocellular carcinoma: a retrospective study |
| Q90620394 | DWI and DCE-MRI approaches for differentiating reversibly electroporated penumbra from irreversibly electroporated ablation zones in a rabbit liver model |
| Q92048062 | Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma |
| Q64947984 | Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. |
| Q64233381 | Effect of HIFU on endometrial receptivity and sex hormone level in uterine fibroid patients and analysis of influencing factors for its treatment rate |
| Q92715444 | Elevated CTSL2 expression is associated with an adverse prognosis in hepatocellular carcinoma |
| Q92617939 | Elevation of miR-191-5p level and its potential signaling pathways in hepatocellular carcinoma: a study validated by microarray and in-house qRT-PCR with 1,291 clinical samples |
| Q92541219 | Evaluation of click chemistry microarrays for immunosensing of alpha-fetoprotein (AFP) |
| Q91813552 | Grape Seed Proanthocyanidins Induce Autophagy and Modulate Survivin in HepG2 Cells and Inhibit Xenograft Tumor Growth in Vivo |
| Q64077600 | Insufficient radiofrequency ablation-induced autophagy contributes to the rapid progression of residual hepatocellular carcinoma through the HIF-1α/BNIP3 signaling pathway |
| Q92062149 | Interpreting the Pharmacological Mechanisms of Huachansu Capsules on Hepatocellular Carcinoma Through Combining Network Pharmacology and Experimental Evaluation |
| Q90398077 | Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model |
| Q64886119 | Liquid biopsies for hepatocellular carcinoma. |
| Q92327875 | Liver Cancer: Current and Future Trends Using Biomaterials |
| Q98623284 | LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma |
| Q64068635 | LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells |
| Q98564748 | LncRNA SNHG14 promotes hepatocellular carcinoma progression via H3K27 acetylation activated PABPC1 by PTEN signaling |
| Q64965074 | MARVELD1 attenuates arsenic trioxide-induced apoptosis in liver cancer cells by inhibiting reactive oxygen species production. |
| Q64274830 | Mechanisms of hepatocellular carcinoma progression |
| Q92501318 | MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R |
| Q58583425 | Microvascular Invasion in HCC: The Molecular Imaging Perspective |
| Q92695097 | Multi-omic Pathway and Network Analysis to Identify Biomarkers for Hepatocellular Carcinoma |
| Q98779341 | Oxytocin receptor genetic alterations in hepatocellular carcinoma |
| Q91886070 | PAK1 promotes proliferation, migration and invasion of hepatocellular carcinoma by facilitating EMT via directly up-regulating Snail |
| Q92352514 | Prognostic roles of the transcriptional expression of exportins in hepatocellular carcinoma |
| Q92618325 | Prognostic value of carbonic anhydrase XII (CA XII) overexpression in hepatocellular carcinoma |
| Q92325380 | Quantitative Tracking Tumor Suppression Efficiency of Human Umbilical Cord-Derived Mesenchymal Stem Cells by Bioluminescence Imaging in Mice Hepatoma Model |
| Q92156901 | Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α |
| Q91785622 | Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma |
| Q89767015 | Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response |
| Q90705657 | Sonic Hedgehog signaling pathway as a potential target to inhibit the progression of hepatocellular carcinoma |
| Q64060436 | The Comprehensive Roles of ATRANORIN, A Secondary Metabolite from the Antarctic Lichen , in HCC Tumorigenesis |
| Q90411487 | The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target |
| Q64108685 | The Proanthocyanidin-Rich Fraction Obtained from Red Rice Germ and Bran Extract Induces HepG2 Hepatocellular Carcinoma Cell Apoptosis |
| Q100958415 | The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma |
| Q64062234 | Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach |
| Q96438252 | lncRNA- RP11-156p1.3, novel diagnostic and therapeutic targeting via CRISPR/Cas9 editing in hepatocellular carcinoma |
| Q90422041 | miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway |
Search more.